CoChat

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Open access
Kopecka, Joanna, Salaroglio, Iris C., Righi, Luisella, Libener, Roberta, Orecchia, Sara, Grosso, Federica, Milosevic, Vladan, Ananthanarayanan, Preeta, Ricci, Luisa, Capelletto, Enrica, Pradotto, Monica, Napoli, Francesca, Di Maio, Massimo, Novello, Silvia, Rubinstein, Menachem, Scagliotti, Giorgio V., Riganti, Chiara · 2018 · Lung Cancer
Cited by 39

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Objectives Cisplatin-based chemotherapy is moderately active in malignant pleural mesothelioma (MPM) due to intrinsic drug resistance and to low immunogenicity of MPM cells. CAAT/enhancer binding protein (C/EBP)-β LIP is a pro-apoptotic and chemosensitizing transcription factor activated in response to endoplasmic reticulum (ER) stress. Materials and methods We investigated if LIP levels can predict the clinical response to cisplatin and survival of MPM patients receiving cisplatin-based chemotherapy. We studied the LIP-dependent mechanisms determining cisplatin-resistance and we identified pharmacological approaches targeting LIP, able to restore cisplatin sensitiveness, in patient-derived MPM cells and animal models. Results were analyzed by a one-way analysis of variance test. Results We found that LIP was degraded by constitutive ubiquitination in primary MPM cells derived from patients poorly responsive to cisplatin. LIP ubiquitination was directly correlated with cisplatin chemosensitivity and was associated with patients' survival after chemotherapy. Overexpression of LIP restored cisplatin's pro-apoptotic effect by activating CHOP/TRB3/caspase 3 axis and up-regulating calreticulin, that triggered MPM cell phagocytosis by dendritic cells and expanded autologous anti-tumor CD8 + CD107 + T-cytotoxic lymphocytes. Proteasome inhibitor carfilzomib and lysosome inhibitor chloroquine prevented LIP degradation. The triple combination of carfilzomib, chloroquine and cisplatin increased ER stress-triggered apoptosis and immunogenic cell death in patients' samples, and reduced tumor growth in cisplatin-resistant MPM preclinical models. Conclusion The loss of LIP mediates cisplatin resistance, rendering LIP a possible predictor of cisplatin response in MPM patients. The association of proteasome and lysosome inhibitors reverses cisplatin resistance by restoring LIP levels and may represent a new adjuvant strategy in MPM treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.lungcan.2018.03.022

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 39

Metadata

Authors
Kopecka, J., Salaroglio, I. C., Righi, L., Libener, R., Orecchia, S., Grosso, F., Milosevic, V., Ananthanarayanan, P., Ricci, L., Capelletto, E., Pradotto, M., Napoli, F., Di Maio, M., Novello, S., Rubinstein, M., Scagliotti, G. V., & Riganti, C.
Venue
Lung Cancer
Publisher
Elsevier BV
Published
2018-06
Volume
120
Pages
34-45
ISSN
0169-5002 (ISSN-L)
OpenAlex
W2792183882
Cited by
39
References
2
FWCI
2.71
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma. https://app.cochat.ai/papers/10.1016/j.lungcan.2018.03.022
The paper
Kopecka, J., Salaroglio, I. C., Righi, L., Libener, R., Orecchia, S., Grosso, F., Milosevic, V., Ananthanarayanan, P., Ricci, L., Capelletto, E., Pradotto, M., Napoli, F., Di Maio, M., Novello, S., Rubinstein, M., Scagliotti, G. V., & Riganti, C. (2018). Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma. Lung Cancer. https://doi.org/10.1016/j.lungcan.2018.03.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.